Our clinical trials

Cantargia’s clinical program



Cantargia’s clinical program

Overview of Cantargia’s clinical studies.



Nadunolimab (CAN04)

The IL1RAP-binding antibody CAN04 is Cantargia’s lead asset and is investigated in multiple clinical trials in combination with chemotherapy or immunotherapy, summarized in the table above. The clinical program for CAN04 primarily focuses on pancreatic cancer (PDAC), triple-negative breast cancer (TNBC) and non-small cell lung cancer (NSCLC).



In the CAN10 project, an additional IL1RAP-targeting antibody is being developed for treatment of inflammatory and autoimmune diseases. The initial focus will be on two severe diseases: myocarditis and systemic sclerosis. In September 2023, CAN10 entered a phase I clinical trial in healthy volunteers and psoriasis patients.